article thumbnail

STAT+: Civica Rx considers moving into chemo drugs as shortages worsen

STAT

WASHINGTON — A nonprofit formed by hospitals to deal with drug shortages is considering a move into chemotherapies. Frustrated by drug shortages and the price spikes that typically ensue, executives from large hospital systems launched the nonprofit Civica Rx to deal with the problem in September 2018.

Hospitals 267
article thumbnail

Roche presents five-year survival outcomes for Tecentriq plus chemotherapy in ES-SCLC

Express Pharma

Results presented from the Phase III IMpower133 study and extension trial IMbrella A, show Roche’s Tecentriq (atezolizumab), in combination with chemotherapy, demonstrates a potential long-term overall survival (OS) benefit as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). 0.91; p=0.0069). 0.91; p=0.0069).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi’s immunotherapy Libtayo gets FDA not in first line lung cancer

pharmaphorum

. “As published in The Lancet, in a prespecified analysis in the subset of patients proven to have PD-L1 expression of at least 50%, Libtayo reduced the risk of death by 43% compared to chemotherapy. In this patient population, Libtayo reduced the risk of death by 32% compared to chemotherapy.

article thumbnail

Immunotherapy to become standard treatment for infants with ALL

European Pharmaceutical Review

Blinatumomab significantly improved survival, with the rate increasing from 66 percent to 93 percent, compared to individuals just given prior chemotherapy. Between 2018 and 2021, 30 children in nine countries were treated with blinatumomab. The treatment was added to the existing chemotherapy, Interfant-06.

article thumbnail

First CAR T-cell therapy recommended on NHS

European Pharmaceutical Review

Through the Cancer Drugs Fund (CDF), in 2018, England was the first European country to provide access to a CAR T-cell therapy to treat these blood cancers. Since then, over 500 patients in England have received axi-cel. CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells.

article thumbnail

Biotech founder arrested in US amid murder-for-hire investigation

pharmaphorum

The co-founder of Los Angeles biotech Enochian Biosciences has been arrested in connection with a federal investigation into the murder of a Vermont man in 2018. The Department of Justice said that Banks is suspected of kidnapping Gregory Davis from his Danville home on 6 January, 2018 and carrying out his murder.

article thumbnail

Failed trial nixes another FDA approval, this time for BMS’ Istodax

pharmaphorum

The HDAC inhibitor was given an accelerated approval by the FDA as a second-line PTCL therapy on the strength of overall response data, but a phase 3 study comparing Istodax to first-line chemotherapy showed no improvement on progression-free survival (PFS).